Today: 7 February 2026
Subscribe
Browse Category

NYSE:ABBV News 25 December 2025 - 8 January 2026

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

New York, January 8, 2026, 05:14 (EST) — Premarket AbbVie Inc (ABBV) shares slipped 1.6% to about $229.64 in premarket trading on Thursday after the drugmaker denied it was in talks to buy cancer biotech Revolution Medicines and cut its 2025 profit view. Revolution’s stock fell 11.5% in extended trading after AbbVie’s statement, Reuters reported. Investing.com+1 The whiplash matters because AbbVie has become a deal story again, and the market is quick to mark it up or down on anything that hints at the next growth lever. The company is due to report full-year and fourth-quarter 2025 results on Feb.
8 January 2026
·····
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

New York, Jan 7, 2026, 18:35 EST — After-hours AbbVie (ABBV.N) shares were down about 1% at $231.11 in after-hours trading on Wednesday after the drugmaker denied a Wall Street Journal report that it was in advanced talks to buy cancer-drug developer Revolution Medicines (RVMD.O), saying it “is not in discussions with Revolution Medicines.” The stock had closed up 4.2% at $233.42, while Revolution shares slid 11.5% late after jumping nearly 30% earlier, with the report pointing to a valuation around $20 billion. AbbVie has spent more than $20 billion on acquisitions since 2023 as its former blockbuster Humira lost
8 January 2026
······
AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

New York, Jan 7, 2026, 16:14 (EST) AbbVie (ABBV.N) is in advanced talks to buy cancer-drug developer Revolution Medicines (RVMD.O), the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Revolution shares jumped nearly 30% after the report, while AbbVie rose more than 5%. https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-talks-buy-biotech-revolution-medicines-wsj-reports-2026-01-07/ For AbbVie, a takeover would also sharpen its push to add new growth drivers as its former blockbuster Humira faces steeper competition after patent protection ended. It would put AbbVie deeper into oncology at a time when big drugmakers are still paying up for late-stage cancer assets. https://www.wsj.com/business/deals/abbvie-near-deal-for-revolution-medicines-eca830a1 The Journal did not
7 January 2026
····
AbbVie stock nudges higher after Canada clears Maviret — what ABBV investors watch next

AbbVie stock nudges higher after Canada clears Maviret — what ABBV investors watch next

New York, January 6, 2026, 12:36 PM ET — Regular session AbbVie shares rose about 0.5% to $221.18 in midday trading on Tuesday after the drugmaker said Health Canada approved its hepatitis C therapy Maviret (glecaprevir/pibrentasvir) for acute and chronic infections. The clearance expands use of an eight-week oral regimen and supports “treat early” strategies aimed at cutting transmission by starting therapy as soon as patients are diagnosed. That matters as investors look for steadier growth drivers and pipeline progress ahead of key investor events this month. AbbVie said Maviret is now approved in Canada for adults and children aged
6 January 2026
····
AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

NEW YORK, Jan 6, 2026, 08:02 EST — Premarket AbbVie shares were flat in premarket trading on Tuesday after the drugmaker said Health Canada had approved its hepatitis C pill Maviret for both acute and chronic infection. AbbVie stock last traded at $220.18. The expanded label matters because it opens the door to treatment soon after diagnosis, when infections are recent and transmission risk can be higher. The company said the eight-week, pan-genotypic regimen — meaning it works across major virus types — is now cleared in Canada for acute and chronic hepatitis C virus (HCV). AbbVie fell 3.98% on
6 January 2026
···
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

New York, Jan 5, 2026, 21:27 EST — Market closed AbbVie Inc shares closed down 4% on Monday at $220.18, lagging a Wall Street rally that pushed the Dow to a record high. The move mattered because drug and biotech names were among the day’s laggards as investors rotated into energy and financials after Venezuela headlines lifted oil-linked stocks. The NYSE Arca Pharmaceutical Index fell about 1.4% and the SPDR S&P Biotech ETF slid 1.1%, while the Health Care Select Sector SPDR ETF dipped 0.3%. Yahoo Finance AbbVie also put a near-term spotlight on its calendar, saying it will present
6 January 2026
·······
AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

NEW YORK, Jan 2, 2026, 14:08 ET — Regular session AbbVie shares ticked higher on Friday after Ironwood Pharmaceuticals, its partner on constipation drug Linzess, raised its 2026 outlook and said it lowered the medicine’s list price at the start of the year. The update matters because Linzess is co-developed and co-commercialized with AbbVie in the U.S., and changes in pricing can shift how much revenue is left after rebates and discounts. It also lands as investors reopen the books for 2026 with drug pricing back on the agenda and macro data next week expected to reset interest-rate bets, a
2 January 2026
·····
AbbVie stock ends 2025 lower as markets shut for New Year — what ABBV investors watch next

AbbVie stock ends 2025 lower as markets shut for New Year — what ABBV investors watch next

NEW YORK, January 1, 2026, 15:38 ET — Market closed AbbVie Inc. shares last closed down 0.5% at $228.49 on Wednesday, the final U.S. trading session of 2025, with Wall Street closed on Thursday for the New Year’s Day holiday. Reuters The market closure matters because AbbVie and other large-cap drugmakers often act as a defensive trade when investors reassess risk at the start of a new year. With liquidity returning in the next session, traders will be watching whether late-December selling pressure persists. Reuters U.S. stocks ended lower on Wednesday, with the S&P 500 down 0.74%, the Nasdaq off
1 January 2026
·····
AbbVie stock slips today as Fed minutes loom in thin year-end trade

AbbVie stock slips today as Fed minutes loom in thin year-end trade

NEW YORK, December 30, 2025, 12:55 ET — Regular session AbbVie Inc. shares fell 0.8% to $228.89 in midday trading on Tuesday. The stock ranged between $228.66 and $231.55 after opening at $230.77, with volume near 795,000 shares. The move came as Wall Street traded with little direction in holiday-thinned turnover, leaving the Dow down 0.24%, the S&P 500 off 0.09% and the Nasdaq lower by 0.07% around midday, Reuters reported. Investors were awaiting minutes from the Federal Reserve’s Dec. 9-10 meeting, when it cut rates by 25 basis points — a quarter of a percentage point — but signaled
30 December 2025
·····
AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

NEW YORK, Dec. 27, 2025, 5:15 PM ET — Market closed. AbbVie Inc. (NYSE: ABBV) heads into the weekend with Wall Street shut and year-end positioning in full swing, after a quiet, post-holiday session on Friday left major U.S. indexes essentially unchanged. In thin trading, investors continue to weigh two competing narratives: a strong 2025 for equities and the seasonally bullish “Santa Claus rally” window — versus the reality that year-end liquidity can amplify moves on any surprise headline. Reuters Where AbbVie stock stands heading into Monday’s sessionAbbVie’s last trade/close sits at $229.98, leaving the stock near the upper end
27 December 2025
·····
AbbVie Stock (ABBV) Before the Market Opens Dec. 26, 2025: Today’s News, Earnings Outlook, Dividend Update, and Analyst Forecasts

AbbVie Stock (ABBV) Before the Market Opens Dec. 26, 2025: Today’s News, Earnings Outlook, Dividend Update, and Analyst Forecasts

AbbVie Inc. (NYSE: ABBV) heads into the post‑Christmas session with shares near recent highs after a strong 2025 run. U.S. exchanges were closed Thursday, Dec. 25 for Christmas, following an early close on Wednesday, Dec. 24, and markets are scheduled to reopen for a full trading day on Friday, Dec. 26. Reuters With the holiday break compressing headlines into fewer sessions—and year‑end positioning often amplifying short‑term moves—investors watching AbbVie stock ahead of the Dec. 26 open are focused on a few durable storylines: Below is what to know before the bell on Friday, Dec. 26, 2025. ABBV stock price check:
26 December 2025
·····
AbbVie (ABBV) Stock on Dec. 25, 2025: After-Hours Check, Today’s Headlines, and What to Watch Before the Dec. 26 Open

AbbVie (ABBV) Stock on Dec. 25, 2025: After-Hours Check, Today’s Headlines, and What to Watch Before the Dec. 26 Open

Dec. 25, 2025 (Thursday) is Christmas Day in the U.S. — and that matters because there was no regular trading session and no closing bell today. U.S. stock markets were closed for the holiday, with the last regular session ending early on Wednesday, Dec. 24. NASDAQ Trader So if you’re checking AbbVie Inc. (NYSE: ABBV) “after the bell” on Dec. 25, what you’re really looking at is the latest available post-close/extended-hours pricing from Dec. 24, plus any fresh news/analysis published today that could influence sentiment when the market reopens Friday, Dec. 26, 2025. Reuters ABBV’s latest price: last close (Dec.
25 December 2025
····
1 2 3 4 5 6 7

Stock Market Today

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

7 February 2026
PLS Group shares closed at A$4.12 Friday, down 1.2% after a 3.7% drop Thursday. Morgan Stanley and Mitsubishi UFJ Financial Group disclosed increased voting power in the lithium miner, both citing changes dated Feb. 2. The moves came as lithium prices fell and Australian equities posted their sharpest drop in months. PLS reports interim results Feb. 19.
Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

7 February 2026
Commonwealth Bank of Australia shares closed at A$158.91, down 0.23% Friday, as the S&P/ASX 200 fell 2.03% and nearly A$70 billion was wiped from the market. The bank reports half-year results and an interim dividend on Feb. 11, with shares going ex-dividend Feb. 18. CBA flagged a A$68 million provision linked to ASIC’s Better Banking review. The RBA raised rates to 3.85% on Feb. 3, with CBA passing on the increase from Feb. 13.
Go toTop